Predictive value of tumor genetic alteration profiling for chemotherapy and EGFR-TKI treatment in advanced NSCLC.
EGFR-TKI
NGS
NSCLC
chemotherapy
tumor genetic alteration profiling
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
27
10
2019
accepted:
14
02
2020
entrez:
9
5
2020
pubmed:
10
5
2020
medline:
10
5
2020
Statut:
ppublish
Résumé
Previous studies have suggested that a variety of tumor driver genetic alterations affected the treatment efficacy of chemotherapy and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC). The present study aimed to investigate the association between the tumor genetic alteration landscape and the treatment outcome of first-line chemotherapy and EGFR-TKIs in advanced NSCLC. A total of 94 patients with advanced NSCLC were recruited. All patients received first-line chemotherapy and/or EGFR-TKIs (either first- or second-generation EGFR-TKI, or third-generation EGFR-TKI) alone or sequentially. Prior to chemotherapy and/or EGFR-TKI treatment, plasma, effusion and/or tumor tissues from the included patients were subjected to next-generation sequencing, targeting 59 genes. The results indicated that the positive genetic alteration status prior to first-line chemotherapy was associated with prolonged progression-free survival (PFS) time compared with the negative status [9.1 vs. 4.0 months; hazard ratio (HR)=6.68; 95% CI, 2.25-19.82; P=0.001). Furthermore, patients with EGFR activating mutation harboring concomitant alterations exhibited a shorter PFS (11.1 vs. 7.4 months; HR=2.14; 95% CI, 1.03-4.44; P=0.04) and overall survival (OS) time [not reached (NR) vs. 32.8 months; HR=4.30; 95% CI, 1.41-13.16; P=0.01] than those without concomitant alterations, with first- and second-generation EGFR-TKI treatment. Similarly, patients with T79M mutation harboring concomitant alterations exhibited a shorter PFS (15.6 vs. 3.6 months; HR=9.48; 95% CI, 2.29-39.28; P=0.002) and OS time (NR vs. 32.8 months; HR=4.85; 95% CI, 1.16-20.29; P=0.03) with osimertinib treatment. Taken together, the results demonstrated that positive genetic alteration status predicted greater efficacy of first-line chemotherapy, while concomitant genetic alterations were associated with poor treatment outcome for first- or second-generation EGFR-TKI and third-generation EGFR-TKI treatment.
Identifiants
pubmed: 32382334
doi: 10.3892/ol.2020.11502
pii: OL-0-0-11502
pmc: PMC7202306
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3859-3870Informations de copyright
Copyright: © Jiang et al.
Références
Expert Opin Ther Targets. 2019 Nov;23(11):893-901
pubmed: 31709855
Cancer. 2019 Mar 15;125(6):892-901
pubmed: 30512189
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Lancet Oncol. 2016 Dec;17(12):1643-1652
pubmed: 27751847
Anticancer Res. 2020 Jan;40(1):109-119
pubmed: 31892559
J Clin Oncol. 2003 Aug 15;21(16):3016-24
pubmed: 12837811
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
J Clin Oncol. 2008 Jul 20;26(21):3543-51
pubmed: 18506025
J Thorac Oncol. 2011 Nov;6(11):1907-14
pubmed: 22005471
Genome Res. 2012 Mar;22(3):568-76
pubmed: 22300766
J Clin Oncol. 2011 Jul 20;29(21):2866-74
pubmed: 21670455
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
JAMA Oncol. 2018 Apr 1;4(4):569-570
pubmed: 29494728
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Oncotarget. 2015 Oct 20;6(32):34014-22
pubmed: 26416458
J Clin Oncol. 2017 Apr 20;35(12):1288-1296
pubmed: 28221867
Lung Cancer. 2014 Mar;83(3):383-8
pubmed: 24439569
Nucleic Acids Res. 2001 Jan 1;29(1):308-11
pubmed: 11125122
Annu Rev Pathol. 2013 Jan 24;8:277-302
pubmed: 23092187
Lancet Oncol. 2017 Nov;18(11):1454-1466
pubmed: 28958502
JAMA Oncol. 2018 May 1;4(5):739-742
pubmed: 29596544
EBioMedicine. 2019 Apr;42:304-310
pubmed: 30878600
Clin Cancer Res. 2013 Apr 15;19(8):2240-7
pubmed: 23470965
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
N Engl J Med. 2015 Apr 30;372(18):1689-99
pubmed: 25923549
BMC Med Genomics. 2012 Jul 02;5:30
pubmed: 22748043
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
Lancet Oncol. 2011 Aug;12(8):735-42
pubmed: 21783417
Lancet Respir Med. 2018 Sep;6(9):681-690
pubmed: 30017884
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
Bioinformatics. 2014 Dec 1;30(23):3390-3
pubmed: 25143292
Ann Oncol. 2007 Feb;18(2):317-23
pubmed: 17079694
Lung Cancer. 2010 Mar;67(3):343-7
pubmed: 19477549
Lung Cancer. 2014 Sep;85(3):408-14
pubmed: 25088661
Clin Cancer Res. 2013 Aug 15;19(16):4532-40
pubmed: 23833300
J Clin Oncol. 2010 Oct 10;28(29):4417-24
pubmed: 20823422
Nat Rev Cancer. 2012 Apr 19;12(5):323-34
pubmed: 22513401
Clin Cancer Res. 2018 Jul 1;24(13):3097-3107
pubmed: 29506987
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168